A mechanistic axis shows LncRNA-ROD binds QKI to prevent degradation of Csf1r mRNA, boosting CSF1R protein levels; knocking down QKI can restore osteoclast differentiation in Runx2−/− and LncRNA-ROD−/− contexts, and both mutants resist OVX-induced bone loss.

LncRNA-ROD is identified as a central regulator of RUNX2-driven osteoclastogenesis and alveolar bone remodeling linked to cleidocranial dysplasia (CCD).

RUNX2 directly activates the non-coding RNA LncRNA-ROD, which is enriched in bone tissue; increasing LncRNA-ROD levels restores impaired osteoclast formation in Runx2-deficient cells.

While the axis influences osteoclast activity and tooth eruption in models, the study notes it does not prove tooth eruption defects can be fully corrected without osteoclast-specific and local alveolar bone experiments.

The findings were published on September 28, 2026, in the International Journal of Oral Science, with News-Medical reporting on the study.

The RUNX2–LncRNA-ROD–QKI axis is proposed as pharmacologically targetable, though targeted alveolar rescue experiments and cell-type specificity considerations are needed before clinical translation.

Rescue experiments suggest the axis is pharmacologically targetable, but validation requires targeted alveolar rescue and cell-type–specific approaches to assess therapeutic potential for tooth eruption defects.

The study provides a framework for distinguishing osteoclast fusion from resorptive capacity and informs strategies for skeletal disorders with altered osteoclast activity, while noting limitations and the need for more targeted models.

The research employs a CCD patient with a RUNX2 missense mutation (c.557G>C; R186T), Runx2+/− mice, LncRNA-ROD knockout/overexpression models, gene-edited cells, RNA pull-down and RNA immunoprecipitation assays, micro-CT, TRAP staining, and OVX experiments.

In vivo data show reduced osteoclast numbers despite some markers suggesting altered fusion, indicating complex regulation of osteoclast activity and bone resorption.

Mutations or deficiency in RUNX2 are linked to CCD, a disorder with delayed eruption of permanent teeth, supernumerary teeth, and clavicle defects; CCD-like changes and reduced osteoclast activity were observed in Runx2-deficient models.

In CCD patients, a RUNX2 missense mutation (c.557G>C; R186T) associates with higher alveolar bone density and absence of TRAP-positive osteoclasts, while Runx2−/− mice show CCD-like skeletal defects and delayed eruption of mandibular first molars.